Seattle Genetics, Inc. (SGEN) Shares Bought by New York State Common Retirement Fund

New York State Common Retirement Fund grew its position in shares of Seattle Genetics, Inc. (NASDAQ:SGEN) by 1.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 265,358 shares of the biotechnology company’s stock after purchasing an additional 4,000 shares during the period. New York State Common Retirement Fund owned approximately 0.19% of Seattle Genetics worth $14,438,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Bristlecone Advisors LLC purchased a new position in shares of Seattle Genetics during the third quarter valued at about $180,000. DRW Securities LLC purchased a new position in Seattle Genetics in the second quarter worth about $207,000. Andra AP fonden purchased a new position in Seattle Genetics in the second quarter worth about $212,000. Tower Research Capital LLC TRC grew its position in Seattle Genetics by 6,835.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,300 shares of the biotechnology company’s stock worth $223,000 after acquiring an additional 4,238 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Seattle Genetics by 6.6% in the second quarter. The Manufacturers Life Insurance Company now owns 4,824 shares of the biotechnology company’s stock worth $250,000 after acquiring an additional 299 shares in the last quarter. Hedge funds and other institutional investors own 98.94% of the company’s stock.

Shares of Seattle Genetics, Inc. (SGEN) opened at $52.55 on Monday. Seattle Genetics, Inc. has a 12 month low of $45.31 and a 12 month high of $71.32.

Seattle Genetics (NASDAQ:SGEN) last announced its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.23. The business had revenue of $135.29 million during the quarter, compared to the consensus estimate of $112.76 million. Seattle Genetics had a negative net margin of 26.53% and a negative return on equity of 32.41%. The firm’s quarterly revenue was up 27.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.23) earnings per share. equities research analysts predict that Seattle Genetics, Inc. will post -0.93 earnings per share for the current fiscal year.

In other Seattle Genetics news, Director Marc E. Lippman sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $58.07, for a total value of $174,210.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Clay B. Siegall sold 18,832 shares of the firm’s stock in a transaction dated Wednesday, October 11th. The stock was sold at an average price of $61.18, for a total transaction of $1,152,141.76. The disclosure for this sale can be found here. In the last three months, insiders sold 157,210 shares of company stock valued at $9,273,250. 34.70% of the stock is owned by insiders.

Several research analysts recently commented on SGEN shares. Cann started coverage on Seattle Genetics in a research report on Wednesday, November 8th. They issued a “hold” rating for the company. Guggenheim reiterated a “buy” rating and issued a $72.00 price target on shares of Seattle Genetics in a research report on Monday, October 23rd. TheStreet upgraded Seattle Genetics from a “d” rating to a “c” rating in a research report on Thursday, November 16th. Goldman Sachs Group reiterated a “neutral” rating and issued a $64.00 price target on shares of Seattle Genetics in a research report on Friday, October 6th. Finally, Jefferies Group reiterated a “buy” rating and issued a $53.00 price target on shares of Seattle Genetics in a research report on Thursday, September 14th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $63.76.

ILLEGAL ACTIVITY NOTICE: This article was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2017/12/18/seattle-genetics-inc-sgen-shares-bought-by-new-york-state-common-retirement-fund.html.

Seattle Genetics Company Profile

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Institutional Ownership by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply